Double-blind, Placebo-controlled Dose-finding Study With CYT003-QbG10 in Adult Patients With Rhinoconjunctivitis Due to House Dust Mite Allergy

NCT00800332 Phase 2 COMPLETED

The purpose of the study is to test whether vaccinations with CYT003-QbG10 can improve allergy symptoms in patients with house dust mite allergy. The active treatment will be compared against placebo.

Details

Lead sponsor	Cytos Biotechnology AG
Phase	Phase 2
Status	COMPLETED
Enrolment	300
Start date	2008-11
Completion	2010-11

Conditions

• Rhinoconjunctivitis
• Allergies

Interventions

• CYT003-QbG10
• Placebo

Primary outcomes

• Rhinoconjunctivitis symptom and medication scores — Pre- / Post-Treatment

Countries

Estonia, Germany, Greece, Latvia, Lithuania, Romania